BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

VentiRx Pharmaceuticals, Inc. Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting Its Potential as an Immunotherapeutic Approach in Cancer


1/23/2012 10:22:46 AM

SEATTLE, Jan. 23, 2012 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of novel Toll-like receptor 8 (TLR8) agonists for the treatment of cancer, today announced the publication of preclinical data demonstrating that VTX-2337, the Company's lead small molecule, is a novel, highly potent and selective TLR8 agonist. VTX-2337 directly activates human myeloid dendritic cells (mDCs), monocytes and natural killer (NK) cells resulting in the production of high levels of mediators known to orchestrate adaptive anti-tumor responses. Data were published in the journal Clinical Cancer Research.

(Logo: http://photos.prnewswire.com/prnh/20120123/SF39404LOGO)

The findings clearly distinguish TLR8 from other human TLRs. TLR8 is expressed on human monocytes, macrophages and mDCs circulating in blood and lymph nodes as well as on dendritic cells that are prevalent throughout the tumor microenvironment. Results demonstrate that the direct activation of mDCs by VTX-2337 results in a uniquely robust production of inflammatory cytokines and chemokines that increase cell mediated immunity and potentially enhance the anticancer effect of standard chemotherapy. Additionally, VTX-2337 has a direct effect on NK cells and augments antibody dependent cellular toxicity (ADCC), which supports the opportunity of combining VTX-2337 with monoclonal antibodies where ADCC contributes to clinical efficacy.

"These preclinical findings underscore the potential of a TLR8 agonist as a promising novel agent for cancer immunotherapy," said Mary L. Disis, M.D., professor of medicine in oncology at the University of Washington and associate dean of translational science at the UW School of Medicine, and co-author of the publication. "This research provides validation for current clinical trials evaluating VTX-2337 in combination with existing cancer treatments."

"VTX-2337 provides unique abilities compared to other TLR agonists in clinical development, most notably a robust and highly selective activation of myeloid dendritic cells and natural killer cells," said Robert Hershberg, M.D., Ph.D., President and Chief Medical Officer of VentiRx. "These preclinical efficacy findings combined with the favorable safety profile of VTX-2337 established in the recently completed Phase 1 trial support the advancement of our broad clinical development program currently underway to evaluate the safety and efficacy of VTX-2337 in combination with standard of care cancer therapies."

VentiRx has advanced VTX-2337 into clinical trials designed to evaluate the compound in multiple oncology indications in combination with a variety of anticancer agents, including chemotherapy and monoclonal antibody therapy. Clinical trials of VTX-2337 currently underway include a combination study with chemotherapy in late stage ovarian cancer and a combination trial with cetuximab in head and neck cancer patients. In addition, a trial of VTX-2337 in combination with chemotherapy in metastatic breast cancer is targeted to begin in mid-2012.

About VentiRx Pharmaceuticals

VentiRx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of cancer. The Company's initial focus is on developing novel small molecule product candidates targeting Toll-based product candidates for oncology and allergy. VentiRx is a privately held organization with operations in Seattle. For additional information, please visit www.ventirx.com.

Contact:

Robert Hershberg, M.D., Ph.D.
President and Chief Medical Officer
VentiRx Pharmaceuticals, Inc.
(206) 689-2268
rhershberg@ventirx.com

Julie Rathbun
Rathbun Communications
(206) 769-9219
julie@rathbuncomm.com

SOURCE VentiRx Pharmaceuticals, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES